Publications by authors named "Maria Delioukina"

Claim this Profile
F
First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.
Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton, Maria Delioukina

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma.
Maria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, Ivan Spicka, Rik Schots, Maria Delioukina

J Oncol Pharm Pract· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Maria Delioukina

Blood Cancer J· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Saad Z Usmani, Hareth Nahi, Wojciech Legiec, Sebastian Grosicki, Vladimir Vorobyev, Maria Delioukina

Haematologica· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Thierry Facon, Shaji K Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Maria Delioukina

Lancet Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study.
Ajai Chari, Paula Rodriguez-Otero, Helen McCarthy, Kenshi Suzuki, Vania Hungria, Maria Delioukina

Br J Haematol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Andre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S Morgan, Maria Delioukina

Blood· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Rare Case of Primary Gastric HIV-Associated Peripheral T-Cell Lymphoma: Relapsed Disease Treated With Pemetrexed.
Jun Gong, Maria L Delioukina, Andrew E Hendifar

World J Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
Steven M Horwitz, Youn H Kim, Francine Foss, Jasmine M Zain, Patricia L Myskowski, Maria L Delioukina

Blood· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
Mark H Kirschbaum, Anthony S Stein, Leslie Popplewell, Maria Delioukina, Robert Chen

Biol Blood Marrow Transplant· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose therapy and autologous hematopoietic cell transplantation in peripheral T cell lymphoma (PTCL): analysis of prognostic factors.
Auayporn Nademanee, Joycelynne M Palmer, Leslie Popplewell, Ni-Chun Tsai, Maria Delioukina

Biol Blood Marrow Transplant· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control.
Jasmine Zain, Joycelynne M Palmer, Maria Delioukina, Sandra Thomas, Ni-Chun Tsai

Leuk Lymphoma· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.
Robert Chen, Joycelynne M Palmer, Leslie Popplewell, Jessica Shen, Eileen Smith, Maria Delioukina

Ann Hematol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular karyotypes of Hodgkin and Reed-Sternberg cells at disease onset reveal distinct copy number alterations in chemosensitive versus refractory Hodgkin lymphoma.
Marilyn L Slovak, Victoria Bedell, Ya-Hsuan Hsu, Dolores B Estrine, Norma J Nowak, Maria L Delioukina

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia.
Maria L Delioukina, Joycelynne M Palmer, Sandra H Thomas, Amrita Krishnan, Tracey Stiller

Leuk Lymphoma· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Mark Kirschbaum, Paul Frankel, Leslie Popplewell, Jasmine Zain, Maria Delioukina

J Clin Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of chronic lymphocytic leukemia by BAC-based microarray analysis.
Roger A Schultz, Maria Delioukina, Karl Gaal, Victoria Bedell, David D Smith

Mol Cytogenet· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?
Maria L Delioukina, Stephen J Forman

Mediterr J Hematol Infect Dis· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Maria L Delioukina, Diane Prager, Mandy Parson, J Randolph Hecht, Peter Rosen

Cancer· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis